Financial figures of the partnership were not disclosed, However, thepartnership with Biokema will enable Amferia’s technology to reach veterinary patients in Switzerland where wound care and infection prevention is of prime importance. With the growing threat of antibiotic-resistant infections globally, Amferia and Biokema’s partnership will build on extensive data collection and feedback from Amferia’s clinical testing across Europe, including Switzerland. The joint efforts aim at marketing the products starting early 2025.